Pharma News

Govt receive Rs 672.28 crore fine from pharma cos for overcharging

  • Posted on: 15 March 2017
  • By: Shalini.Sharma

Since its inception, the National Pharmaceutical Pricing Authority (NPPA) has published 1,527 notices of demand to companies for surcharges on sales of formulations at prices above the notified ceiling price. Drug price regulator NPPA received Rs 672.28 fine crore up to date from pharmaceutical companies for overcharge, Parliament was informed.


CDSCO collaborate with ICMR to develop 'Handbook for Applicants and Reviewers of Clinical Trials of New Drugs in India'

  • Posted on: 14 March 2017
  • By: Shalini.Sharma

The Indian Council of Medical Research (ICMR) and the Central Drugs Standard Control Organization (CDSCO) have jointly developed a 'Handbook for Applicants and Reviewers of Clinical Trials of New Drugs in India'. The main objective is to guide applicants and reviewers of clinical trial applications and commercialization (import, manufacture, sale) of new experimental drugs (INDs) and new drugs (NDs) in the country


ICMR will conduct clinical trials to evaluate drugs and vaccines against tuberculosis

  • Posted on: 10 March 2017
  • By: Shalini.Sharma

Taking into account strict national and international guidelines for the conduct of clinical trials, ICMR has decided to undertake clinical trials for regulatory submissions and for academic purposes. India is a signatory to the WHO Global Tuberculosis Strategy, which was endorsed by the World Health Assembly in May 2014.


Delhi HC Confirms Order Resigning Sale of Cipla Respiratory Disease Drug

  • Posted on: 10 March 2017
  • By: Shalini.Sharma

A Divisional Court of the Delhi High Court upheld a single judgment ordering Cipla to be restricted from selling its respiratory illness - Indaflo. Cipla launched the drug on the Indian market in 2014 under the name Unibrez, while demanding the revocation of five Novartis patents on Indacaterol, the generic version of respiratory medicine.


Drug-resistant tuberculosis could soon have access to new drugs

  • Posted on: 8 March 2017
  • By: Shalini.Sharma

Patients suffering from drug-resistant tuberculosis may soon have access to Delamanid, one of two new drugs to get approval for the treatment of tuberculosis after more than 40 years. The drug was added to the kitty shrinking choices to treat multi-drug resistant (MDR) and resistant to resistant tuberculosis (XDR) shortly after bedaquiline.


Pages